Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;45(5):627-633.
doi: 10.1007/s13318-020-00629-1.

Development and Stability Study of an Omeprazole Suppository for Infants

Petra Bestebreurtje  1 , Nel Roeleveld  2 , Catherijne A J Knibbe  3   4 , Adriaan A van Sorge  5 , Frans B Plötz  6   7 , Saskia N de Wildt  8   9
Affiliations

Development and Stability Study of an Omeprazole Suppository for Infants

Petra Bestebreurtje et al. Eur J Drug Metab Pharmacokinet. 2020 Oct.

Abstract

Background and objective: Omeprazole is a proton pump inhibitor (PPI) that is used in acid suppression therapy in infants. In this study we aimed to develop a pediatric omeprazole suppository, with good physical and chemical stability, suitable for pharmaceutical batch production.

Methods: The composition of the suppository consisted of omeprazole, witepsol H15 and arginine (L) base. To achieve evenly distributed omeprazole suspension suppositories, the temperature, stirring rate, and arginine (L) base amount were varied. A previously validated quantitative high-performance liquid chromatography-ultraviolet method was modified and a long-term stability study was performed for one year.

Results: Evenly distributed omeprazole suspension suppositories were obtained by adding 100 mg arginine (L) base and pouring at a temperature of 34.7 °C and a stirring speed of 200 rpm. The long-term stability study showed no signs of discoloration and a stable omeprazole content between 90 and 110% over 1 year if stored in the dark at room temperature.

Conclusion: We developed a pediatric omeprazole suppository. This formulation may provide a good alternative to manipulated commercial or extemporaneously compounded omeprazole oral formulations for infants. Clinical studies are needed to establish efficacy and safety in this young population.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Average omeprazole concentration over time for omeprazole 3 mg (a) and omeprazole 10 mg (b) suppositories under different storage conditions
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet. 1991;20:38–49. doi: 10.2165/00003088-199120010-00003. - DOI - PubMed
    1. Rosen R, Vandenplas Y, Singendonk M, Cabana M, Dilorenzo C, Gottrand F, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatric Gastroenterol Nutr. 2018;66:516–554. doi: 10.1097/MPG.0000000000001889. - DOI - PMC - PubMed
    1. Peetsold MG, Kneepkens CF, Heij HA, IJsselstijn H, Tibboel D, Gemke RJ. Congenital diaphragmatic hernia: long-term risk of gastroesophageal reflux disease. J Pediatric Gastroenterol Nutr. 2010;51:448–453. doi: 10.1097/MPG.0b013e3181d1b149. - DOI - PubMed
    1. Tovar J, Fragoso A. Gastroesophageal reflux after repair of esophageal atresia. Eur J Pediatr Surg. 2013;23:175–181. doi: 10.1055/s-0033-1347911. - DOI - PubMed
    1. Marseglia L, Manti S, D’Angelo G, Gitto E, Salpietro C, Centorrino A, et al. Gastroesophageal reflux and congenital gastrointestinal malformations. World J Gastroenterol. 2015;21:8508. doi: 10.3748/wjg.v21.i28.8508. - DOI - PMC - PubMed

LinkOut - more resources